Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.46 |
| ▸ | LTA4H | P09960 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.33 |
| ▸ | METTL3 | Q86U44 | 1/20 | 0.33 |
| ▸ | METTL14 | Q9HCE5 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7169172 | 0.91 | MAPT (0.54) | NPC1ALDH1A1POLBMAPTRAB9A | |
| SCHEMBL27923079 | 0.78 | ALDH1A1 (0.57) | NPC1ALDH1A1POLBMAPTRAB9A | |
| SCHEMBL1849445 | 0.76 | RAB9A (0.62) | NPC1ALDH1A1POLBMAPTRAB9A | |
| SCHEMBL942764 | 0.75 | ALDH1A1 (0.65) | NPC1ALDH1A1POLBMAPTRAB9A | |
| SCHEMBL7069544 | 0.74 | ALOX15 (0.39) | POLBLTA4HEPHX2CA2CYP4A11 | |
| SCHEMBL81999 | 0.73 | LTA4H (0.56) | SMN1; SMN2LTA4HEPHX2CA2HDAC2 | |
| SCHEMBL8623391 | 0.73 | LTA4H (0.56) | SMN1; SMN2LTA4HEPHX2CA2HDAC2 | |
| SCHEMBL3535251 | 0.73 | CA2 (0.54) | ALDH1A1MAPTMEN1KMT2AHRH3 | |
| SCHEMBL1853028 | 0.73 | ALDH1A1 (0.62) | NPC1ALDH1A1POLBMAPTRAB9A | |
| SCHEMBL873426 | 0.73 | ALDH1A1 (0.62) | NPC1ALDH1A1POLBMAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6572664-B2 | Oxidation dyeing of keratin fibers | L'OREAL S.A. (FR) | 2003-06-03 | — | — | US | claimed |
| US-20020170121-A9 | Indolizine derivatives, compositions comprising at least one coupler chosen from indolizine derivatives and at least one oxidation base, and methods for using same | L'OREAL S.A. (FR) | 2002-11-21 | — | — | US | claimed |
| US-20020002749-A1 | Indolizine derivatives, compositions comprising at least one coupler chosen from indolizine derivatives and at least one oxidation base, and methods for using same | BRETON PHILIPPE (FR) | 2002-01-10 | — | — | US | claimed |
| EP-1129691-A2 | Compositions for dyeing keratinous fibers containing indolizine derivatives and dyeing method using same | L'OREAL (FR) | 2001-09-05 | — | — | EP | claimed |
| US-6572664-B2 | Oxidation dyeing of keratin fibers | L'OREAL S.A. (FR) | 2003-06-03 | — | — | US | disclosed |
| US-20020170121-A9 | Indolizine derivatives, compositions comprising at least one coupler chosen from indolizine derivatives and at least one oxidation base, and methods for using same | L'OREAL S.A. (FR) | 2002-11-21 | — | — | US | disclosed |
| US-20020002749-A1 | Indolizine derivatives, compositions comprising at least one coupler chosen from indolizine derivatives and at least one oxidation base, and methods for using same | BRETON PHILIPPE (FR) | 2002-01-10 | — | — | US | disclosed |
| EP-1129691-A2 | Compositions for dyeing keratinous fibers containing indolizine derivatives and dyeing method using same | L'OREAL (FR) | 2001-09-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020002749-A1 | Indolizine derivatives, compositions comprising at least one coupler chosen from indolizine derivatives and at least one oxidation base, and methods for using same | KRT18, INMT, IDO1 | NPC1 4832/4885ALDH1A1 897/4885POLB 833/4885 |
| US-20020170121-A9 | Indolizine derivatives, compositions comprising at least one coupler chosen from indolizine derivatives and at least one oxidation base, and methods for using same | KRT18, INMT, IDO1 | NPC1 4832/4885ALDH1A1 897/4885POLB 833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.